Related Experiment Video

Updated: Mar 26, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

1.3K

Therapeutic advances in idiopathic pulmonary fibrosis

Emily Fraser1, Rachel K Hoyles2

  • 1Oxford Interstitial Lung Disease Service, Churchill Hospital, Oxford, UK.

Clinical Medicine (London, England)
|February 3, 2016
PubMed

Insights

Idiopathic pulmonary fibrosis (IPF) management has advanced with pirfenidone and nintedanib, slowing disease progression. This review covers IPF care, specialist roles, and practical use of these new anti-fibrotic therapies.

Area of Science:

  • Pulmonology
  • Fibrotic Lung Diseases
  • Pharmacology

Background:

  • Idiopathic pulmonary fibrosis (IPF) is a progressive lung scarring condition with a poor prognosis.
  • Limited effective treatment options existed previously, including palliative care and anti-inflammatory therapies.
  • Recent breakthroughs have introduced novel anti-fibrotic agents.

Purpose of the Study:

  • To outline current management strategies for IPF.
  • To discuss the role of specialist centers and multidisciplinary teams in IPF care.
  • To review the evidence and practical application of pirfenidone and nintedanib in IPF treatment.

Main Methods:

  • Review of clinical trial data for pirfenidone and nintedanib.
  • Analysis of current guidelines and expert opinions on IPF management.
  • Discussion of practical considerations for implementing anti-fibrotic therapy.

Main Results:

  • Pirfenidone and nintedanib have demonstrated efficacy in slowing IPF progression.
  • Specialist multidisciplinary review is crucial for optimal patient management.
  • Evidence supports the use of these agents in specific IPF patient populations.

Conclusions:

  • Pirfenidone and nintedanib represent significant advancements in IPF treatment.
  • A multidisciplinary approach is essential for effective IPF management.
  • Further research and real-world data will refine the use of anti-fibrotic therapies.
Keywords:
IPFanti-fibrotic agentsidiopathic pulmonary fibrosisnintedanibpirfenidone

More Related Videos

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models03:38

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Published on: June 20, 2025

1.1K
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

2.2K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
597
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
633
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
733
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
2.2K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
616
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.3K